Literature DB >> 8598755

Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bileduct calculi in high-risk patients.

E M Targarona1, R M Ayuso, J M Bordas, E Ros, I Pros, J Martínez, J Terés, M Trías.   

Abstract

BACKGROUND: Morbidity and mortality after surgical treatment of bileduct stones increase with age and associated diseases. A proposed alternative therapy is endoscopic sphincterotomy (ES) with the gallbladder left in situ, and we elected to compare this option with standard open surgery in high-risk patients.
METHODS: 98 patients (mean age 80 years) with symptoms likely to be due to bileduct stones or a recent episode of biliary pancreatitis were randomised to be treated either by open cholecystectomy with operative cholangiography and (if necessary) bileduct exploration (n=48) or by endoscopic sphincterotomy alone (n=50).
FINDINGS: The procedure was accomplished successfully in 94% of the surgery group and 88% of the ES group, and there were no significant differences in immediate morbidity (23% vs 16%) or mortality (4% vs 6%). During mean follow-up of 17 months biliary symptoms recurred in three surgical patients, none of whom underwent repeat surgery, and in 10 ES patients, seven of whom had biliary surgery. By multivariate regression analysis endoscopic sphincterotomy was an independent predictor of recurrent biliary symptoms (odds ratio 6.9; 95% Cl 1.46 to 32.54).
INTERPRETATION: In elderly or high-risk patients, surgery is preferable to endoscopic sphincterotomy with the gallbladder left in situ as a definitive treatment for bileduct stones or non-severe biliary pancreatitis.

Entities:  

Mesh:

Year:  1996        PMID: 8598755     DOI: 10.1016/s0140-6736(96)91413-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  39 in total

1.  Endoscopic treatment of bile duct stones in elderly people.

Authors:  T C Tham; D L Carr-Locke
Journal:  BMJ       Date:  1999-03-06

2.  Routine laparoscopic cholecystectomy after endoscopic sphincterotomy for choledocholithiasis in octogenarians: is it worth the risk?

Authors:  R Costi; D DiMauro; A Mazzeo; A S Boselli; S Contini; V Violi; L Roncoroni; L Sarli
Journal:  Surg Endosc       Date:  2006-11-16       Impact factor: 4.584

3.  ERCP and endoscopic sphincterotomy (ES): a safe and definitive management of gallstone pancreatitis with the gallbladder left in situ.

Authors:  Mark Bignell; Matthew Dearing; Andrew Hindmarsh; Michael Rhodes
Journal:  J Gastrointest Surg       Date:  2011-10-18       Impact factor: 3.452

4.  Gallstone pancreatitis--who really needs an ERCP?

Authors:  M F Byrne
Journal:  Can J Gastroenterol       Date:  2006-01       Impact factor: 3.522

Review 5.  Biliary pancreatitis.

Authors:  George Sarosi; Robert V Rege
Journal:  J Gastrointest Surg       Date:  2006 Sep-Oct       Impact factor: 3.452

6.  Evidence-based treatment of acute pancreatitis: a look at established paradigms.

Authors:  Stefan Heinrich; Markus Schäfer; Valentin Rousson; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

7.  Risk factors of acute cholecystitis after endoscopic common bile duct stone removal.

Authors:  Jun Kyu Lee; Ji Kon Ryu; Joo Kyung Park; Won Jae Yoon; Sang Hyub Lee; Kwang Hyuck Lee; Yong-Tae Kim; Yong Bum Yoon
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

8.  Management of common bile duct stones: controversies and future perspectives.

Authors:  Eduardo M Targarona; Gali Even Bendahan
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

9.  Timing of cholecystectomy for biliary pancreatitis: do the data support current guidelines?

Authors:  Kaori Ito; Hiromichi Ito; Edward E Whang
Journal:  J Gastrointest Surg       Date:  2008-07-18       Impact factor: 3.452

Review 10.  Long-term results from laparoscopic common bile duct exploration.

Authors:  A Waage; C Strömberg; C-E Leijonmarck; D Arvidsson
Journal:  Surg Endosc       Date:  2003-05-13       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.